|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's Range||38.01 - 43.78|
|52 Week Range||9.50 - 43.81|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 03, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.82|
Subscribe to Yahoo Finance Plus to view Fair Value for VTYX
The consensus price target hints at a 39% upside potential for Ventyx Biosciences, Inc. (VTYX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Phase 2 clinical trials of VTX958 (TYK2 inhibitor) in plaque psoriasis, Crohn’s disease and psoriatic arthritis are ongoing with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis is on track to complete enrollment by mid-2023; new pharmacodynamic data support best-in-class potential Releases new data highlighting attractive profiles of NLRP3 inhibitors VTX2735 and VTX3232 Discloses new small molecule discovery program
Ventyx Biosciences, Inc. (VTYX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.